-
Original Article
-
Korean J Med. 2006;71(4):449-455.
- 증례:비호지킨 림프종에서 리툭시맙 투여에 의한 간질성 폐질환 1예
-
최영준, , , , , ,
-
- A case of interstitial lung diseasec caused by Rituximab in non-Hodgkin lymphoma
-
Young Jun Choi, Woo Jin Jung, Se Il Oh, Min Hoyk Jeon, Hee Jung Sohn, Eun Mee Han, Cheolwon Suh
-
고려대학교 의과대학 내과학교실
-
- Abstract
- Rituximab targets CD20+ B cells and has been used increasingly for the treatment of B-cell
Non-Hodgkin Lymphoma, alone or in combination with cytotoxic agents. Rituximab can kill
CD20+cells by multiple mechanisms. Rituximab therapy has often been associated with an
infusion-related symptom complex consisting of fever, chills, and rigors that is usually self-limited.
These complications are transient without long-term effects. Several delayed pulmonary events
involving interstitial reactions and bronchiolitis obliterans with organizing pneumonia have recently
been described in conjunction with the use of Rituximab. In the lymphoma patient presented here
there was no respiratory symptoms; however, respiratory difficulty developed after the third round
of Rituximab plus CHOP chemotherapy. High resolution computed tomography (HRCT) and positive
emission tomography (PET) were performed and revealed diffuse ground glass opacities.
We report a patient with Non-Hodgkin Lymphoma in whom interstitial lung disease developed
after Rituximab therapy.(Korean J Med 71:449-455, 2006)
Key Words : Rituximab, Non-Hodgkin Lymphoma, Interstitial Lung Disease
Keywords :
